In Denmark systemic treatment with high dose Interleukin 2/Interferon (IL-2/IFN – Keilholz decrescendo regime [21]) is 1st line treatment for patients with metastatic malignant melanoma. The gene discussed is IL2; the disease is metastatic melanoma.